John Lazarchick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Lazarchick has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Amanda Fowler
Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA
1 shared publicationAmarendra K. Neppalli
Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA
1 shared publicationCynthia A. Schandl
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA
1 shared publicationD. Cherry
†Department of Pathology, Trident Medical Center, Charleston, South Carolina, USA
1 shared publicationDanyel Bourgeois
From the Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston
1 shared publicationG. R. Post
Department of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
1 shared publication
Latest Publications
- 1 May 2019
- Vol. 49 (3) , 393-394
A Novel Case of Compound Heterozygous Type 3 Von Willebrand Disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder worldwide. Genetic mutations in the von Willebrand gene may result in either quantitative (Types 1 or 3) or qualitative defects (Type 2) of von Willebrand Factor (vWF). Type 3 is the rarest and most severe form of VWD, resulting in a virtual absence of vWF. Type 3 VWD follows autosomal recessive inheritance and is most often reported in patients who are homozygous for the same gene mutation. We report a patient with type 3 VWD who inherited two different mutations, one from each parent, resulting in compound heterozygosity.
- 1 May 2019
- Vol. 49 (3) , 393-394
A Novel Case of Compound Heterozygous Type 3 Von Willebrand Disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder worldwide. Genetic mutations in the von Willebrand gene may result in either quantitative (Types 1 or 3) or qualitative defects (Type 2) of von Willebrand Factor (vWF). Type 3 is the rarest and most severe form of VWD, resulting in a virtual absence of vWF. Type 3 VWD follows autosomal recessive inheritance and is most often reported in patients who are homozygous for the same gene mutation. We report a patient with type 3 VWD who inherited two different mutations, one from each parent, resulting in compound heterozygosity.
- 1 September 2017
- Vol. 47 (5) , 611-619
IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review
IgM multiple myeloma (MM) is a rare entity representing approximately 0.5% of all MM. It should be distinguished from malignant neoplasms of B cells with plasmacytic differentiation such as Waldenstrom macroglobulinemia (WM) and marginal zone lymphoma with plasmacytic differentiation. Plasma cell leukemia (PCL) is a rare and aggressive variant of MM characterized by the presence of circulating plasma cells. We present a case report of a patient who presented with IgM MM in primary PCL phase with high-risk cytogenetics. To our knowledge, this is the first reported case of IgM MM with primarily leukemic presentation in the era of novel drugs. We demonstrate that it is important to distinguish IgM MM from WM and review the data from clinical trials that was used to devise a treatment strategy for this high-risk patient. This case adds to the understanding of the diagnosis and management of IgM MM in leukemic phase.
- 1 September 2017
- Vol. 47 (5) , 611-619
IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review
IgM multiple myeloma (MM) is a rare entity representing approximately 0.5% of all MM. It should be distinguished from malignant neoplasms of B cells with plasmacytic differentiation such as Waldenstrom macroglobulinemia (WM) and marginal zone lymphoma with plasmacytic differentiation. Plasma cell leukemia (PCL) is a rare and aggressive variant of MM characterized by the presence of circulating plasma cells. We present a case report of a patient who presented with IgM MM in primary PCL phase with high-risk cytogenetics. To our knowledge, this is the first reported case of IgM MM with primarily leukemic presentation in the era of novel drugs. We demonstrate that it is important to distinguish IgM MM from WM and review the data from clinical trials that was used to devise a treatment strategy for this high-risk patient. This case adds to the understanding of the diagnosis and management of IgM MM in leukemic phase.
- 1 March 2017
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 353 (3) , 207-215
Characterization of Mast Cell Activation Syndrome
- 1 March 2017
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 353 (3) , 207-215
Characterization of Mast Cell Activation Syndrome
- 1 January 2016
- Vol. 46 (2) , 209-12
Diagnosing Spindle Cell Variant of Primary Cutaneous B-Cell Lymphoma: Potential Pitfalls and Solutions.
Spindle cell variant of cutaneous B-cell lymphoma is a rare entity which poses a diagnostic difficulty. The differential diagnosis of cutaneous spindle cell lesions is broad, and often includes sarcoma, carcinoma, and melanoma. Lymphoma with spindle cell morphology is frequently only considered after exclusion of more common etiologies. Among these rare cases of lymphoma with spindle cell morphology, a majority prove to be of B-cell origin. Following the diagnosis of cutaneous lymphoma, a thorough clinical evaluation must be conducted to determine if the lesion represents primary cutaneous lymphoma or secondary cutaneous involvement by a systemic process, as these have distinct classifications, prognoses, and treatments.
- 1 January 2016
- Vol. 46 (2) , 209-12
Diagnosing Spindle Cell Variant of Primary Cutaneous B-Cell Lymphoma: Potential Pitfalls and Solutions.
Spindle cell variant of cutaneous B-cell lymphoma is a rare entity which poses a diagnostic difficulty. The differential diagnosis of cutaneous spindle cell lesions is broad, and often includes sarcoma, carcinoma, and melanoma. Lymphoma with spindle cell morphology is frequently only considered after exclusion of more common etiologies. Among these rare cases of lymphoma with spindle cell morphology, a majority prove to be of B-cell origin. Following the diagnosis of cutaneous lymphoma, a thorough clinical evaluation must be conducted to determine if the lesion represents primary cutaneous lymphoma or secondary cutaneous involvement by a systemic process, as these have distinct classifications, prognoses, and treatments.
- 1 January 2012
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 19 (1) , 58-60
Update on anemia and neutropenia in copper deficiency
Copper deficiency is an under-recognized cause of reversible refractory anemia and leukopenia, particularly neutropenia, often misdiagnosed as myelodysplastic syndrome (MDS). Clinicians and hematopathologists need to be aware of distinct morphologic findings to distinguish these entities including cytoplasmic vacuolization of both erythroid and myeloid precursors, excess iron stores, ringed sideroblasts, iron incorporation in plasma cells, and variable marrow cellularity. In contrast, the findings in MDS do not include myeloid lineage vacuolization, abnormal nuclear lobulation of both erythroid and myeloid precursors, nuclear/cytoplasmic dyssynchrony, or dysmegakaryopoiesis with abnormalities of nuclear lobulation and size. The mechanism of neutropenia remains unknown; however, the study by Peled and coworkers suggests that copper deficiency results in the inhibition of differentiation and self-renewal of CD34(+) hematopoietic progenitor cells. A number of recent studies have reported on the association of copper deficiency with the development of concomitant neurologic deficits manifested as peripheral neuropathies and myeloneuropathy indistinguishable from the findings seen in vitamin B12 deficiency. Patients presenting with refractory anemia and leukopenia with or without associated neurologic deficits should have copper and ceruloplasmin levels measured as part of their diagnostic evaluation.
- 1 January 2012
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 19 (1) , 58-60
Update on anemia and neutropenia in copper deficiency
Copper deficiency is an under-recognized cause of reversible refractory anemia and leukopenia, particularly neutropenia, often misdiagnosed as myelodysplastic syndrome (MDS). Clinicians and hematopathologists need to be aware of distinct morphologic findings to distinguish these entities including cytoplasmic vacuolization of both erythroid and myeloid precursors, excess iron stores, ringed sideroblasts, iron incorporation in plasma cells, and variable marrow cellularity. In contrast, the findings in MDS do not include myeloid lineage vacuolization, abnormal nuclear lobulation of both erythroid and myeloid precursors, nuclear/cytoplasmic dyssynchrony, or dysmegakaryopoiesis with abnormalities of nuclear lobulation and size. The mechanism of neutropenia remains unknown; however, the study by Peled and coworkers suggests that copper deficiency results in the inhibition of differentiation and self-renewal of CD34(+) hematopoietic progenitor cells. A number of recent studies have reported on the association of copper deficiency with the development of concomitant neurologic deficits manifested as peripheral neuropathies and myeloneuropathy indistinguishable from the findings seen in vitamin B12 deficiency. Patients presenting with refractory anemia and leukopenia with or without associated neurologic deficits should have copper and ceruloplasmin levels measured as part of their diagnostic evaluation.
- 1 July 2010
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 8 (2) , 84-88
PAX-5: A Valuable Immunohistochemical Marker in the Differential Diagnosis of Lymphoid Neoplasms
Undifferentiated tumors and hematolymphoid neoplasms can be diagnostically challenging due to potential overlap of morphologic features and variant antigen expression. PAX-5, a transcription factor expressed throughout B-cell maturation, is detected in most B-cell neoplasms including those that lack expression of mature B-cell markers, such as classical Hodgkin lymphoma (cHL), B-lymphoblastic leukemia and B-cell lymphomas following rituximab therapy. The lack of PAX-5 expression in most CD30-positive non-hematopoietic malignancies (embryonal carcinoma and seminoma) and T-cell lymphomas, such as anaplastic large cell lymphoma (ALCL), suggests that the absence of PAX-5 may be used to confirm non-B-cell lineage. The goal of this study was to retrospectively assess PAX-5 immunoreactivity in diagnostic samples of hematolymphoid and other non-hematopoietic malignancies. Diagnostic lymph node, decalcified core bone marrow biopsies and tissue sections from 111 archived paraffin-embedded tissue blocks and a tissue lymphoma microarray were immunostained using a monoclonal antibody to PAX-5. The corresponding hematoxylin and eosin stained tissue sections and additional immunostains were simultaneously evaluated. PAX-5 immunoreactivity in neoplastic cells was scored as positive or negative. This study was exempted by the Institutional Review Board for Human Research. Nuclear PAX-5 immunoreactivity was detected in 88% (36/41) of Hodgkin lymphoma, all cases of diffuse large B-cell lymphoma (n=72), small B-cell lymphomas (n=5), B-lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia with B-cell lineage (n=5). PAX-5 was not detected in ALCL (n=22), T-cell lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemia with T-cell lineage (n=5), acute myeloid leukemia (n=4), carcinoid tumors with typical morphology (n=5), melanoma (n=3), and undifferentiated/metastatic tumors (n=8). Non-neoplastic bone marrow sections showed scattered nuclear staining in small B-cell lymphocytes/hematogones. The detection of PAX-5 immunoreactivity resulted in the reclassification of two cases of ALCL to cHL. Overall, our results demonstrate that including PAX-5 in a panel with other immunomarkers helps establish B-cell lineage and increases diagnostic yield.
- 1 July 2010
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 8 (2) , 84-88
PAX-5: A Valuable Immunohistochemical Marker in the Differential Diagnosis of Lymphoid Neoplasms
Undifferentiated tumors and hematolymphoid neoplasms can be diagnostically challenging due to potential overlap of morphologic features and variant antigen expression. PAX-5, a transcription factor expressed throughout B-cell maturation, is detected in most B-cell neoplasms including those that lack expression of mature B-cell markers, such as classical Hodgkin lymphoma (cHL), B-lymphoblastic leukemia and B-cell lymphomas following rituximab therapy. The lack of PAX-5 expression in most CD30-positive non-hematopoietic malignancies (embryonal carcinoma and seminoma) and T-cell lymphomas, such as anaplastic large cell lymphoma (ALCL), suggests that the absence of PAX-5 may be used to confirm non-B-cell lineage. The goal of this study was to retrospectively assess PAX-5 immunoreactivity in diagnostic samples of hematolymphoid and other non-hematopoietic malignancies. Diagnostic lymph node, decalcified core bone marrow biopsies and tissue sections from 111 archived paraffin-embedded tissue blocks and a tissue lymphoma microarray were immunostained using a monoclonal antibody to PAX-5. The corresponding hematoxylin and eosin stained tissue sections and additional immunostains were simultaneously evaluated. PAX-5 immunoreactivity in neoplastic cells was scored as positive or negative. This study was exempted by the Institutional Review Board for Human Research. Nuclear PAX-5 immunoreactivity was detected in 88% (36/41) of Hodgkin lymphoma, all cases of diffuse large B-cell lymphoma (n=72), small B-cell lymphomas (n=5), B-lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia with B-cell lineage (n=5). PAX-5 was not detected in ALCL (n=22), T-cell lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemia with T-cell lineage (n=5), acute myeloid leukemia (n=4), carcinoid tumors with typical morphology (n=5), melanoma (n=3), and undifferentiated/metastatic tumors (n=8). Non-neoplastic bone marrow sections showed scattered nuclear staining in small B-cell lymphocytes/hematogones. The detection of PAX-5 immunoreactivity resulted in the reclassification of two cases of ALCL to cHL. Overall, our results demonstrate that including PAX-5 in a panel with other immunomarkers helps establish B-cell lineage and increases diagnostic yield.
- Open Access
- 1 July 2005
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 129 (7) , 950-952
Lymphadenopathy in a 3-Year-Old Boy 17 Months After Bone Marrow Transplantation for Acute Myeloid Leukemia (AML-M5a)
- 1 July 2005
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 129 (7) , 950-952
Open AccessLymphadenopathy in a 3-Year-Old Boy 17 Months After Bone Marrow Transplantation for Acute Myeloid Leukemia (AML-M5a)
- 3 May 2004
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 43 (1) , 66-69
CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia
A 9‐month‐old infant presented with hypercalcemia and lytic bone lesions. Suspicion for malignancy led to a bone marrow examination, which showed replacement of the marrow by a small round blue cell infiltrate. Flow cytometric analysis of these cells showed an unusual immunophenotype in that these cells were dim CD45, HLA‐DR, and CD10 positive, but CD19, CD20, CD79a, and CD34 negative. Southern blotting showed clonal rearrangement of immunoglobulin heavy chain (IgH) which confirmed a diagnosis of precursor B acute lymphoblastic leukemia (ALL). He received supportive treatment with hydration and pamidronate, but had recurrent episodes of hypercalcemia. Once the correct diagnosis of ALL was established, the patient was treated with an infantile ALL chemotherapeutic regimen and the hypercalcemia resolved. This case highlights the usefulness of immunoglobulin gene rearrangement studies in atypical cases of ALL.
- 3 May 2004
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 43 (1) , 66-69
CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia
A 9‐month‐old infant presented with hypercalcemia and lytic bone lesions. Suspicion for malignancy led to a bone marrow examination, which showed replacement of the marrow by a small round blue cell infiltrate. Flow cytometric analysis of these cells showed an unusual immunophenotype in that these cells were dim CD45, HLA‐DR, and CD10 positive, but CD19, CD20, CD79a, and CD34 negative. Southern blotting showed clonal rearrangement of immunoglobulin heavy chain (IgH) which confirmed a diagnosis of precursor B acute lymphoblastic leukemia (ALL). He received supportive treatment with hydration and pamidronate, but had recurrent episodes of hypercalcemia. Once the correct diagnosis of ALL was established, the patient was treated with an infantile ALL chemotherapeutic regimen and the hypercalcemia resolved. This case highlights the usefulness of immunoglobulin gene rearrangement studies in atypical cases of ALL.